O Shaughnessy Asset Management LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

O Shaughnessy Asset Management LLC purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 8,617 shares of the biopharmaceutical company's stock, valued at approximately $259,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Blue Trust Inc. lifted its holdings in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 371 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp increased its stake in TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 1,737 shares during the last quarter. Synergy Asset Management LLC acquired a new stake in TG Therapeutics during the fourth quarter worth approximately $75,000. Finally, GAMMA Investing LLC lifted its position in shares of TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 2,171 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

TG Therapeutics Stock Performance

TGTX traded down $1.28 during trading on Wednesday, hitting $37.75. The stock had a trading volume of 906,219 shares, compared to its average volume of 3,102,213. TG Therapeutics, Inc. has a twelve month low of $12.93 and a twelve month high of $43.32. The firm has a market capitalization of $5.93 billion, a P/E ratio of -377.46 and a beta of 2.14. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company's 50-day moving average price is $35.98 and its 200 day moving average price is $31.60.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. On average, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TGTX has been the subject of several research analyst reports. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.